Loading filters...
Publications per Year (1657 total)
6
·
5
·
15
·
9
1995
13
·
21
·
23
·
19
·
34
2000
37
·
29
·
37
·
30
·
40
2005
48
·
41
·
38
·
50
·
53
2010
56
·
75
·
78
·
80
·
73
2015
65
·
75
·
70
·
79
·
61
2020
80
·
67
·
70
·
64
·
95
2025
21
·
Loaded
Click to load
50 / 1657 papers loaded(scroll for more)
202621 papers
RAI-refractoryAll Stages2026
The Patterns and Risk Factors for Antidepressant Drug Prescription in Thyroid Cancer Patients and Survivors: Analysis Based on the Korean National Health Insurance Service Database.
Kang YE et al. Thyroid. 2026
RAI-refractoryAdvanced/Metastatic2026
Molecular Profile of Advanced Radioiodine-refractory Thyroid Cancer and Response to Lenvatinib Treatment.
Minaldi E et al. J Clin Endocrinol Metab. 2026
AnaplasticAdvanced/Metastatic2026
Health-related Quality of Life with Encorafenib plus Binimetinib for BRAFV600E Thyroid Cancer.
Kiyota N et al. Eur Thyroid J. 2026
RAI-refractoryAdvanced/Metastatic2026
Initial Evaluation of Radioiodine Therapy Using Imaging for Long-term Prognosis in Thyroid Cancer: A Retrospective Study.
Nakatani R et al. J Clin Endocrinol Metab. 2026
RAI-refractoryAdvanced/Metastatic2026
Approach to the patient: Oncocytic thyroid cancer.
Finnegan EA et al. J Clin Endocrinol Metab. 2026
RET alteredAll Stages2026
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.
Waliany S et al. Clin Cancer Res. 2026
RAI-refractoryAdvanced/Metastatic2026
Molecular Profiling and Real-world Outcomes of BRAF V600E-Mutated Papillary Thyroid Cancer.
Chirra M et al. Clin Cancer Res. 2026
RET alteredAdvanced/Metastatic2026
Real-world external control arm for the single-arm LIBRETTO-001 trial of selpercatinib in RET-mutation-positive medullary thyroid cancer: RECALIB-RET.
Hadoux J et al. ESMO Open. 2026
RAI-refractoryAll Stages2026
Precautionary Behaviors and Side Effects after Radioiodine for Thyroid Disease: A Prospective Cohort Study.
Yielder R et al. Thyroid. 2026
RAI-refractoryAll Stages2026
TERT promoter mutations and recurrence patterns in differentiated thyroid carcinoma.
Ryu HJ et al. Endocr Relat Cancer. 2026
TKIAdvanced/Metastatic2026
Real-world data show limited efficacy of sequential cabozantinib treatment in RAIR-(P)DTC.
Machlah YM et al. Endocr Relat Cancer. 2026
BRAF V600EAdvanced/Metastatic2026
Anlotinib Plus Sintilimab for BRAFV600E Negative Unresectable or Metastatic Anaplastic Thyroid Carcinoma: A Single-Center, Single-Arm, Phase 2 Trial.
Gui L et al. Thyroid. 2026
AnaplasticAdvanced/Metastatic2026
ALK Inhibition Prolongs Survival in a Mouse Model of ALK-Positive Anaplastic Thyroid Cancer.
Machlah YM et al. Thyroid. 2026
Anaplasticearly2026
Long-term Survivors of Anaplastic Thyroid Cancer: A Genomic Predictive Model.
Greenspun BC et al. J Clin Endocrinol Metab. 2026
RAI-refractoryAll Stages2026
Exposure to GLP-1RA and risk of structural progression in differentiated thyroid cancer.
Patrizio A et al. J Clin Endocrinol Metab. 2026
TKIAdvanced/Metastatic2026
Real-World Experience with Lenvatinib plus Pembrolizumab in Metastatic BRAF Wild-Type Anaplastic Thyroid Carcinoma.
Hamidi S et al. Thyroid. 2026
RAI-refractoryAll Stages2026
Defining the ATA-2025 'consider RAIT' zone in older patients with N1b PTC.
Wang Z et al. Endocr Relat Cancer. 2026
AnaplasticAll Stages2026
FOSL1 Orchestrates Epigenetic Reprogramming of Anaplastic Thyroid Cancer and Suppresses Natural Killer Cell-Mediated Antitumor Immunity.
Huo Y et al. Cancer Res. 2026
RAI-refractoryAll Stages2026
Pre-Radioiodine Thyrotropin Thresholds During Withdrawal Preparation in Differentiated Thyroid Cancer after Total Thyroidectomy: A Systematic Review and Meta-Analysis.
Rojas T et al. Thyroid. 2026
AnaplasticAdvanced/Metastatic2026
Characterization of Advanced RAS-driven Follicular-derived Thyroid Cancers and Review of Future Therapeutic Avenues.
Hamidi S et al. J Clin Endocrinol Metab. 2026
AnaplasticAll Stages2026
Nrf2 shapes response to lysosomal inhibition of radiation-induced senescent thyroid cancer cells.
Mazzoleni B et al. Endocr Relat Cancer. 2026
202529 papers
RAI-refractoryAdvanced/Metastatic2025
Next-generation sequencing of targetable gene fusions in radioiodine-refractory thyroid cancer: a multicenter study.
Yoo J et al. Endocr Relat Cancer. 2025
RAI-refractoryAdvanced/Metastatic2025
Molecular predictive biomarker testing in advanced thyroid cancer - a European consensus.
Ryška A et al. Eur Thyroid J. 2025
RAI-refractoryAdvanced/Metastatic2025
Long-Term Clinical Outcomes of Patients with Differentiated Thyroid Cancer Treated with Lenvatinib: Results from Real-World Practice in Japan.
Onaga R et al. Thyroid. 2025
RAI-refractoryAll Stages2025
Targeting Src tyrosine kinase to enhance radioiodide uptake in breast cancer.
Poole VL et al. Endocr Relat Cancer. 2025
RAI-refractoryAll Stages2025
Thyroid Cancer Survivors Experience Persistent Symptoms and Health-Related Quality-of-Life Deficits 12 Months Following Surgery.
O'Neill CJ et al. Thyroid. 2025
RAI-refractoryAll Stages2025
Development and validation of long-acting recombinant human TSH using SAFA technology.
Kim D et al. Endocr Relat Cancer. 2025
RAI-refractoryAll Stages2025
2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer.
Ringel MD et al. Thyroid. 2025
RAI-refractoryAll Stages2025
Predictive factors of radioiodine ablation success: results from a MEDIRAD prospective clinical study for thyroid cancer.
Taprogge J et al. Eur Thyroid J. 2025
RAI-refractoryAdvanced/Metastatic2025
TSHR in thyroid cancer: bridging biological insights to targeted strategies.
Xu S et al. Eur Thyroid J. 2025
RAI-refractoryAdvanced/Metastatic2025
Differentiated thyroid cancer in two European referral centres: impact of different diagnostic and therapeutic strategies.
Ceruti D et al. Eur Thyroid J. 2025
RAI-refractoryAll Stages2025
Clinical and Pathological Factors Associated with Disease Persistence in Pediatric Patients with Differentiated Thyroid Carcinoma.
De Leo S et al. Thyroid. 2025
RAI-refractoryAll Stages2025
Contribution of Germline Predisposition to Pediatric Thyroid Cancer.
Harrison C et al. Clin Cancer Res. 2025
RAI-refractoryAll Stages2025
Thyroid Carcinoma in Birt-Hogg-Dubé Syndrome: Case Series and Review of Literature.
Vaid S et al. Thyroid. 2025
RAI-refractoryAll Stages2025
Risk-adapted therapy in pediatric thyroid cancer: initial experience from a national reference program by the MET group.
Kuhlen M et al. Eur Thyroid J. 2025
RAI-refractoryAdvanced/Metastatic2025
Approach to the Patient With Thyroid Cancer: Selection and Management of Candidates for Lobectomy.
Robenshtok E et al. J Clin Endocrinol Metab. 2025
RAI-refractoryAdvanced/Metastatic2025
Clinical outcomes of malignant pleural effusion in patients with lung metastases from differentiated thyroid cancer.
Kim CA et al. Endocr Relat Cancer. 2025
RAI-refractoryAll Stages2025
Clinical differences and surgery in follicular vs oncocytic thyroid carcinomas.
Xiang J et al. Endocr Relat Cancer. 2025
RAI-refractoryAdvanced/Metastatic2025
Impact of molecular tests and precision oncology on patients with advanced thyroid carcinomas in a referral center: the OrienTHYring real-world study.
Colombo E et al. ESMO Open. 2025
TKIAdvanced/Metastatic2025
TP53 Alterations Are Associated With Poor Response to Lenvatinib in Patients With Advanced Thyroid Cancer.
Cirello V et al. J Clin Endocrinol Metab. 2025
RAI-refractoryAdvanced/Metastatic2025
A Systematic Review of Absorbed Doses and Response in Patients Treated with Radioiodine for Differentiated Thyroid Cancer.
Taprogge J et al. Thyroid. 2025
TKIAdvanced/Metastatic2025
Management of Adverse Events During Treatment for Advanced Thyroid Cancer.
Roberts TJ et al. Thyroid. 2025
RAI-refractoryAll Stages2025
Thyroglobulin Cutoffs after Total Thyroidectomy Without Radioiodine in Low- to Intermediate-Risk Thyroid Cancer: A Multicenter Cohort Study.
Kim M et al. Thyroid. 2025
RAI-refractoryAll Stages2025
Are Total Thyroidectomy and Adjuvant Radioactive Iodine Treatment Required in All Patients with N1b Intermediate-High Risk Papillary Thyroid Carcinoma?
Fujiwara T et al. Thyroid. 2025
RAI-refractoryAll Stages2025
Clinical relevance of the thyroid differentiation score (TDS) in benign and malignant thyroid tumors.
Muzza M et al. Endocr Relat Cancer. 2025
RAI-refractoryAll Stages2025
Dynamic risk stratification in patients with follicular thyroid carcinoma treated with lobectomy.
Yamazaki H et al. Eur Thyroid J. 2025
RAI-refractoryAll Stages2025
Genetic modification of the AJCC classification of papillary thyroid cancer: an international, multicentre, retrospective cohort study.
Xing M et al. Lancet Oncol. 2025
RAI-refractoryearly2025
Dynamic Risk Assessment Using Unstimulated Serum Thyroglobulin Level and Thyroglobulin Doubling Rate after Total Thyroidectomy for Papillary Thyroid Carcinoma.
Ito Y et al. Thyroid. 2025
RAI-refractoryAdvanced/Metastatic2025
Anlotinib in progressive RAI-refractory differentiated thyroid cancer: long-term results and PET/CT prognostic markers.
Sun D et al. Endocr Relat Cancer. 2025
TKIAll Stages2025
Lenvatinib as an urgent initial therapy in thyroid cancer with remarkable laryngotracheal invasion.
Katoh H et al. Eur Thyroid J. 2025